Primary Myelofibrosis clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
Optimal Dose Finding Study of N-Acetylcysteine in Patients with Myeloproliferative Neoplasms
open to eligible people ages 18 years and up
This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).
Irvine, California and other locations
Our lead scientists for Primary Myelofibrosis research studies include Angela G. Fleischman.
Last updated: